YM155 (Sepantronium Bromide)

For research use only. Not for use in humans.

目录号:S1130

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

YM155 (Sepantronium Bromide)是一种有效的survivin抑制药,通过抑制Survivin启动子活性而发挥作用,在HeLa-SURP-luc 和 CHO-SV40-luc细胞中IC50为0.54 nM;对SV40启动子活性抑制作用不显著,能够轻微抑制Survivin与XIAP相互作用。YM155 在乳腺癌细胞中可下调 survivinXIAP、调节自噬并诱导自噬依赖的DNA损伤。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 918.45 现货
RMB 568.29 现货
RMB 983.81 现货
RMB 2214.29 现货
RMB 6310.26 现货
RMB 10401.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的YM155 (Sepantronium Bromide)发表文献133篇:

产品安全说明书

Survivin抑制剂选择性比较

生物活性

产品描述 YM155 (Sepantronium Bromide)是一种有效的survivin抑制药,通过抑制Survivin启动子活性而发挥作用,在HeLa-SURP-luc 和 CHO-SV40-luc细胞中IC50为0.54 nM;对SV40启动子活性抑制作用不显著,能够轻微抑制Survivin与XIAP相互作用。YM155 在乳腺癌细胞中可下调 survivinXIAP、调节自噬并诱导自噬依赖的DNA损伤。Phase 2。
靶点
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
体外研究

YM155 30 μM时对SV40作用效果也不大。在p53缺陷的PC-3和PPC-1 人类HRPC细胞中,通过抑制 survivin基因启动子的转录,YM155显著抑制内源性survivin的表达。相反,YM155 100 nM时对c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin,及β-tubulin的蛋白表达仍没抑制效果。YM155作用于人类癌细胞系包括PC-3和PPC-1,使细胞发生凋亡,伴随着caspase-3活性上升。YM155有效抑制人类癌细胞系(突变p53或短小p53) 包括PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5及A375 ,IC50值为2.3到11 nM。[1]另外,YM155增强NSCLC细胞对γ-射线的敏感性。YM155和γ-射线联用,增强凋亡细胞数和caspase-3活性。 YM155推迟修复放射诱导核DNA断裂的双链。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPoXphUPzJiaB?= MonnSG1UVw>? MmPLTWM2OD1yLkCwPUDDuSByLkCwNFkh|ryP Mn7DNlU3PTl5M{G=
M-07e MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\4O|IhcA>? MlHySG1UVw>? NYTQcIh1UUN3ME2wMlA1OCEEsTCwMlAyOyEQvF2= NHrtW5YzPTZ3OUezNS=>
THP-1 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe3NkBp MVrEUXNQ Mo\1TWM2OD1yLkC1NUDDuSByLkCxN{DPxE1? NFPpUHAzPTZ3OUezNS=>
CMK MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXzVY44OiCq MVnEUXNQ MWrJR|UxRTBwMEWzJOKyKDBwMEC5JO69VQ>? MnH5NlU3PTl5M{G=
MV4-11 NHjvUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK3RY1xPzJiaB?= NGj4OmVFVVOR NFnPU4JKSzVyPUCuNFU2KMLzIECuNFI5KM7:TR?= M1;n[|I2PjV7N{Ox
AML-193 NX20R2hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13yS|czKGh? Mn7ISG1UVw>? NE[5UGZKSzVyPUCuOFYzKMLzIECuNFYxKM7:TR?= NFjk[4kzPTZ3OUezNS=>
HL-60 NVrLVpdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC3NkBp NVLDZ25MTE2VTx?= MXvJR|UxRTBwMECxJOKyKDBwMECwNkDPxE1? MY[yOVY2QTd|MR?=
ML-2 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG5bmpNPzJiaB?= MnPwSG1UVw>? M2[3bmlEPTB;MD6wNFkhyrFiMD6wNFIh|ryP NGe5UFIzPTZ3OUezNS=>
OCI/AML3 MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfiO|IhcA>? MX3EUXNQ MkH2TWM2OD1yLkCxNUDDuSByLkCwNkDPxE1? NV65OoVMOjV4NUm3N|E>
HEL NYjjXpN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjMO|IhcA>? M3rhRmROW09? M4XkTGlEPTB;MD61OVkhyrFiMD6wN|gh|ryP NXv4bI12OjV4NUm3N|E>
ME-1 NHWzZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUO3NkBp MYDEUXNQ M1XvPGlEPTB;MD62PFQhyrFiMD6xO|kh|ryP MkDENlU3PTl5M{G=
THP-1 MWrBdI9xfG:|aYOgRZN{[Xl? MXGxxsDPxE1? MXi3NkBp MYLEUXNQ MV\pcoR2[2W|IHHwc5B1d3Orcx?= NYTQeoxDOjV4NUm3N|E>
M-07e Ml\zSpVv[3Srb36gRZN{[Xl? NIjzUGgx6oDVMdMg{txO MoPmO|IhcA>? M4fLXmROW09? NVnrc4xjcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MoPkNlU3PTl5M{G=
THP-1 MVXGeY5kfGmxbjDBd5NigQ>? M2jpNlDjiJNzwrFOwG0> Mn;CO|IhcA>? NVXzeVg1TE2VTx?= NEnucVJqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu MmnKNlU3PTl5M{G=
CMK NFLqW2tHfW6ldHnvckBCe3OjeR?= NIr3NGUx6oDVMdMg{txO NYrXWHZJPzJiaB?= M1fWVWROW09? MWXpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw M3Pj[FI2PjV7N{Ox
AML-193 MXrGeY5kfGmxbjDBd5NigQ>? NHjES4Ix6oDVMdMg{txO NEHiWZo4OiCq M3Ln[GROW09? MVfpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NYnEN2RkOjV4NUm3N|E>
Kasumi-1 MWPGeY5kfGmxbjDBd5NigQ>? Mn7sNQKBmzIEoN88US=> NVzoRWVTPzJiaB?= M4LpfmROW09? M2jKSYlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NHnOUW4zPTZ3OUezNS=>
MV4-11 NIfuSIJHfW6ldHnvckBCe3OjeR?= NIjyVWYx6oDVMdMg{txO M2XVRVczKGh? MVjEUXNQ NF;uN3NqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu NXP0fHNMOjV4NUm3N|E>
MUG-Chor  MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPKc|JDOC13IN88US=> NInZb5czPC92ODDo Ml\NTWM2OD15LkC15qCKdk1iZn;yJFQ5cA>? MXKyOVY1ODF6NR?=
U-CH1  NYO2c5k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWwMVUh|ryP MoHqNlQwPDhiaB?= NW\HXVdwUUN3ME25MlA{6oDLbl2g[o9zKDR6aB?= MUKyOVY1ODF6NR?=
KATOIII MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrWNVAwOjBibl2= Moe4OFghcA>? NVL3cnVYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGXZXm8zPTZ|NUC1OS=>
AGS  M1m4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HZcFExNzJyIH7N M2DmRlQ5KGh? NUjoeoU3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmfONlU3OzVyNUW=
SACC-83 MVfGeY5kfGmxbjDBd5NigQ>? M2G1VFUhdk1? NITmUng1QCCq Ml:x[IVkemWjc3XzJI52[2ynYYKg[ZhxemW|c3nvckBw\iCKSV[tNe6y MXuyOVQ5PTZ|NR?=
INA-6 M3fRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGwMVUxOCCwTR?= NUnVfIlGPDhiaB?= MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVmyOVI6Pjl5OB?=
U-266 NUPZPZBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvOdIhYOC13MECgcm0> NFv1WXM1QCCq NFnxRpBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWiyOVI6Pjl5OB?=
MOLP-8 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ntSFAuPTByIH7N MkfNOFghcA>? M3XZb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4W3ZlI2Ojl4OUe4
HG-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzkUVVpOC13MECgcm0> NW\0NZdGPDhiaB?= M{PZOolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmrMNlUzQTZ7N{i=
NCI-H929 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zXRlAuPTByIH7N NUjkOJlQPDhiaB?= NYSzXWM5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3PWelI2Ojl4OUe4
OPM-2 M36zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHPNYZ{OC13MECgcm0> Mn\VOFghcA>? M4f1cYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWqyOVI6Pjl5OB?=
L-363 NELkOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7obYUxNTVyMDDuUS=> MX60PEBp NWPhPYREcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1f6fVI2Ojl4OUe4
MOLP-2 NUHCdGtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXm[2cxNTVyMDDuUS=> Ml7uOFghcA>? NWLoNGZlcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVvFbndUOjV{OU[5O|g>
KMS-12-BM MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjRbHRmOC13MECgcm0> NGjFT2Y1QCCq MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWqyOVI6Pjl5OB?=
SK-MM-2 Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LlcFAuPTByIH7N NH;pPWg1QCCq MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVyyOVI6Pjl5OB?=
U-266 MUfBdI9xfG:|aYOgRZN{[Xl? Mn\BNE02OCCwTR?= M2j6elI1KGh? NVS2fYo6cW6mdXPld{BieG:ydH;zbZM> NX3EUZZkOjV{OU[5O|g>
INA-6  NFzTcZFCeG:ydH;zbZMhSXO|YYm= MYCwMVUxKG6P M{foN|I1KGh? MXzpcoR2[2W|IHHwc5B1d3Orcx?= Mn7XNlUzQTZ7N{i=
MCF7 M1PZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvIN2pnPzJiaB?= MnPjTWM2OD1zMzFCtUA3KG6P NHXiO2IzPTJ{MEKyOS=>
MCF7-TamR6 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfhXpJmPzJiaB?= M{C2Z2lEPTB;ODFCtUA3KG6P MmjWNlUzOjB{MkW=
MCF7-TamR7 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XuNFczKGh? NX;Ue5ZiUUN3ME24JOKyKDNibl2= M4\uc|I2OjJyMkK1
MCF7-TamR8 NIPoO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnN[WM4OiCq MXXJR|UxRTF3INMxJFYhdk1? NHXrR3QzPTJ{MEKyOS=>
MCF7-TamC3 M3XEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWK3NkBp MVnJR|UxRTZiwsGgN{BvVQ>? MX:yOVIzODJ{NR?=
MCF7-TamC6 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3kepk4OiCq M1zCNGlEPTB;NjFCtUAxNjFibl2= MXmyOVIzODJ{NR?=
MDA-MB-231 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLyO|IhcA>? NXXKb4wzUUN3ME21JOKyKDFibl2= NVzsSoFxOjV{MkCyNlU>
SK-BR-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTxO|IhcA>? NHjGXndKSzVyPUegxtEhOC5|IH7N NInDVJgzPTJ{MEKyOS=>
Eca109 NYPNeWFHTnWwY4Tpc44hSXO|YYm= MYWxMVUxKG6P MVy0PEBp NWDXUXRZTE2VTx?= M3PoTJN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MlfENlUyOzl|OUW=
TE13 NFjGNFFHfW6ldHnvckBCe3OjeR?= Mm\ONU02OCCwTR?= NY\mNXRvPDhiaB?= NFG4fnVFVVOR M4mzSpN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MUKyOVE{QTN7NR?=
Eca109 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[wMVExOCCwTR?= MlvZNlQwPDhiaB?= M{DtcGROW09? NWTwS21{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFe5W4kzPTF|OUO5OS=>
TE13 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[wMVExOCCwTR?= MWWyOE81QCCq NH;OXWpFVVOR NG\oSGhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M4TTO|I2OTN7M{m1
MT-3 M3LaSWtqdmG|ZTDBd5NigQ>? NXnl[pNFPzJiaB?= MV7EUXNQ MnHmTWM2OD1{Lki2JOKyKDBwNUSgcm0h\m:{IFTSOEBmgHC{ZYPzbY9v NGWyfVkzPDh4NkW4OS=>
MDA-MB-468 M3rnUGtqdmG|ZTDBd5NigQ>? M37ZVlczKGh? MVjEUXNQ NGLOTZZKSzVyPUCuNVEhyrFiMD6wNUBvVSCob4KgSHI1KGW6cILld5Nqd25? M1rXWlI1QDZ4NUi1
SUM-159 MnvpT4lv[XOnIFHzd4F6 M4qxcFczKGh? M{ewPGROW09? MYfJR|UxRTFwN{KgxtEhOC5|MzDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> NVXTVVZMOjR6Nk[1PFU>
MT-3 NF7pbYlMcW6jc3WgRZN{[Xl? MYW3NkBp NXfUdXh{TE2VTx?= NYT2SllJUUN3ME21OE4yOSEEsTC0MlMzKG6PIH\vdkBFWjViZYjwdoV{e2mxbh?= M1HoeVI1QDZ4NUi1
MDA-MB-468 M4TLXGtqdmG|ZTDBd5NigQ>? NYi2fGh2PzJiaB?= NV\qOG9GTE2VTx?= M{HQNGlEPTB;MD6wO{DDuSByLkCyJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? MkDMNlQ5PjZ3OEW=
SUM-159 M4L3cGtqdmG|ZTDBd5NigQ>? M4jKWVczKGh? NU\BfYMzTE2VTx?= MorQTWM2OD14OT60JOKyKDRwMkOgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v MYKyOFg3PjV6NR?=
MT-3 + NAC MUHLbY5ie2ViQYPzZZk> MmntO|IhcA>? MXfEUXNQ NFXwZ3VKSzVyPUW2MlIhyrFiMj6wO{BvVSCob4KgSHI2KGW6cILld5Nqd25? NXjzOI9jOjR6Nk[1PFU>
MT-3 + SB203580 MXfLbY5ie2ViQYPzZZk> MYO3NkBp MkTwSG1UVw>? MXjJR|UxRTN6LkSxJOKyKDVwMEKgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v MkDqNlQ5PjZ3OEW=
DB M4jWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNEBvVQ>? M3fzNFI1KGh? MWTEUXNQ Mk\xbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u M{j5eVI1PDh4NUm1
SU-DHL-8 NF;EelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nwXFExKG6P NI\hXlIzPCCq MkWySG1UVw>? Ml\vbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u MnHoNlQ1QDZ3OUW=
WSU-DLCL2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fvNVExKG6P NWDF[HRiOjRiaB?= MlLpSG1UVw>? NFX1OmdqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> NGe1fWYzPDR6NkW5OS=>
ACC-2 NU\Zd4tJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MViwMVExOCCwTR?= NFjOb2YzPCCq NEP3XGRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mk\INlQ{PzB7OUW=
ACC-2 NHi3XYtCeG:ydH;zbZMhSXO|YYm= MYewMVIxKG6P NHHncmozPCCq MUDpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXKyOFM4ODl7NR?=
ACC-2 NVn1NXBCTnWwY4Tpc44hSXO|YYm= MUewMVIxKG6P MoPmNlQhcA>? NXX6dlJ4cW6lcnXhd4V{KHSqZTDjc453\XK|aX;uJI9nKEyFM1mgeI8hVEN|SVm= M4nreVI1OzdyOUm1
BFTC905 NXrzT4tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHtNE0yODByIH7N MnTsOFghcMLi M3POdmROW09? MY\JR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXnNZ5hHOjR{OUe2OFQ>
T24 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TXTVAuOTByMDDuUS=> NHGyRVk1QCCqwrC= MoO2SG1UVw>? M{naXWlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NELVfYszPDJ7N{[0OC=>
TSGH8301  NHPFSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXINE0yODByIH7N MlLDOFghcMLi Mo\1SG1UVw>? NX7IcG97UUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M330flI1Ojl5NkS0
BFTC909 M3u2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[yO|AuOTByMDDuUS=> MYe0PEBpyqB? M4Owc2ROW09? NHTYN3ZKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWHpR4ZuOjR{OUe2OFQ>
BFTC905 NELnc4JCeG:ydH;zbZMhSXO|YYm= MlvYNlAhdk1? NV:xVZhnPDhiaB?= NF\tdZFFVVOR M1X0e4lv\HWlZYOgZZBweHSxc3nz MUeyOFI6PzZ2NB?=
BFTC905 MY\GeY5kfGmxbjDBd5NigQ>? MWeyNEBvVQ>? NIjxd|A1QCCq NFLwV5RFVVOR M3r5O4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzOELVnJ NIPIWG0zPDJ7N{[0OC=>
A2780p MlzFSpVv[3Srb36gRZN{[Xl? NXr2[WhVOC1zMECgcm0> NGPacm4zPCCq M1i0cGROW09? M3y2PYlv\HWlZYOgV5Vzfmm4aX6g[I94dnKnZ4XsZZRqd28EoB?= NFrSb4kzPDJ4Mki3OS=>
A2780cis NUTxPFl5TnWwY4Tpc44hSXO|YYm= M2HUSVAuOTByIH7N MnHFNlQhcA>? NFftTYpFVVOR M2PxVYlv\HWlZYOgV5Vzfmm4aX6g[I94dnKnZ4XsZZRqd28EoB?= M2fLXlI1OjZ{OEe1
A2780p M{HoeWFxd3C2b4Ppd{BCe3OjeR?= NUPYNoJuPS1zMECgcm0> MXqyOE81QCCq NW\EXnRSTE2VTx?= MUXpcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy M4LIflI1OjZ{OEe1
A2780cis M3PsPGFxd3C2b4Ppd{BCe3OjeR?= M3\DPFUuOTByIH7N MoCzNlQwPDhiaB?= NXfXXJZWTE2VTx?= NFvEdY1qdmO{ZXHz[ZMh[XCxcITvd4l{KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MX6yOFI3Ojh5NR?=
SH-SY5Y M2HyN2Fxd3C2b4Ppd{BCe3OjeR?= M33QeFEwOTBxMUCwJOK2VQ>? M4PJ[VczKGh? NHzseo5FVVOR NVPDcIZIcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1K4TVI1OjV2NU[w
HL-60 NYHtWFRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke5O|LDqGh? NWK3PXRyTE2VTx?= NXu1OmF7UUN3ME2wMlMhdk1? MnPDNlM3OTh6NkK=
U937  M1LiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\lfGQ4OsLiaB?= NGDaZlVFVVOR NVjXW|dIUUN3ME2wMlghdk1? M4jxfFI{PjF6OE[y
HL-60  M3zqc2Z2dmO2aX;uJGF{e2G7 M2XlfFHDqM7:TR?= MXi2M|EzNzJ2IHi= NHLCfIZFVVOR NGm1ZldqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=> NWr4VWY1OjN4MUi4OlI>
U937  MVfGeY5kfGmxbjDBd5NigQ>? MVGxxsDPxE1? Mn\COk8yOi9{NDDo NVzDfHc6TE2VTx?= M1jVSIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu NHn0PYgzOzZzOEi2Ni=>
HL-60 M{XHVWFxd3C2b4Ppd{BCe3OjeR?= M3TydFAvOS9zIN88US=> NYDUSYpmQCCq MmrwSG1UVw>? M4ezTYlv\HWlZYOgZZBweHSxc3nz NV62RYtROjN4MUi4OlI>
Sk-NEP-1  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexMVExODByIH7N M4TwW|I1KGh? M1O0PWROW09? MX3JR|UxRTFyMDDuUS=> NHvVTnMzOzJ4N{[5PS=>
SK-NEP-1  NHe1SWNCeG:ydH;zbZMhSXO|YYm= NIewUWM2OC9zMECgcm0> NVHpT4tQOTJxMkSgbC=> NF3LeoNFVVOR NYjVOoZrcW6mdXPld{BieG:ydH;zbZM> MmXoNlMzPjd4OUm=
TC-32 NWi3cHFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn2fXMxNjFvMUCwNEBvVQ>? M4HVTWVEPTB;Mz6wJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVyyNlk3OTd4Mx?=
TC-71 MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vYeFAvOS1zMECwJI5O MYnFR|UxRTVwNzDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4\YbFIzQTZzN{[z
SK-ES-1 NWKwcY4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TFN|AvOS1zMECwJI5O MYjFR|UxRTJwODDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVWyNlk3OTd4Mx?=
RD-ES MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Lxd|AvOS1zMECwJI5O MkTKSWM2OD14LkKgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1;sc|IzQTZzN{[z
HEK293 NE\rRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe2NE4yNTFyMECgcm0> NFfubWtGSzVyPUKzMlAhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVqyNlk3OTd4Mx?=
M059J M4XzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG0NE02OCCwTR?= MYC0PEBp NXzsblFOcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWTsXphMOjJ5N{CxNVA>
M059K NEXvbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnCZo8xNTVyIH7N NEKzXIE1QCCq MnPMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIjjcmYzOjd5MEGxNC=>
M059J NGHxPG5CeG:ydH;zbZMhSXO|YYm= M1XzclMxKG6P NEXrTI0zPCCq NG\QeIhqdmS3Y3XzJIFxd3C2b4Ppdy=> MXSyNlc4ODFzMB?=
M059K M{LFXmFxd3C2b4Ppd{BCe3OjeR?= MYezNEBvVQ>? NVnpRlNjOjRiaB?= NYrQT5ZScW6mdXPld{BieG:ydH;zbZM> MYeyNlc4ODFzMB?=
PANC-1 NVq3SopUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVqwMlAyNTFyMECgcm0> MX20PEBp MX7JR|UxRTNwNkmgcm0> NHHrdJczOjd{M{i3NS=>
MIAPaCa-2 M1nRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT4NE4xOS1zMECwJI5O M2C4OlQ5KGh? NUDxZVVxUUN3ME2yPU4{PiCwTR?= MmTnNlI4OjN6N{G=
BxPC-3 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWwMlAyNTFyMECgcm0> M4rLXVQ5KGh? NXH2T4ROUUN3ME2zNE4zPiCwTR?= NV[5fpdWOjJ5MkO4O|E>
PANC-1 M3THRmZ2dmO2aX;uJGF{e2G7 NFfRPZMxNTFyMECgcm0> MojvNlQhcA>? NUKzbWhScW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v MXuyNlczOzh5MR?=
MIAPaCa-2 M{DlRWZ2dmO2aX;uJGF{e2G7 MVmwMVExODBibl2= Mm\6NlQhcA>? NWfjdHJ4cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v NWXlS2hPOjJ5MkO4O|E>
BxPC-3 NFj4RZhHfW6ldHnvckBCe3OjeR?= NEDJd40xNTFyMECgcm0> MYiyOEBp MWLpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= NFjNNFQzOjd{M{i3NS=>
RPMI-7951 NH7tVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK1S2k2OD1|LkKgcm0> MXWyNVc{PzVyMh?=
SK-MEL-5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m5NmdKPTB;ND6yJI5O Ml7jNlE4Ozd3MEK=
A375 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvWS2k2OD14LkOgcm0> NX:5fJhwOjF5M{e1NFI>
SK-MEL-28 MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLvRWRIUTVyPUeuOkBvVQ>? M1ywdFIyPzN5NUCy
SK-MEL-2 NFLqUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LuWmdKPTB;MUGgcm0> MonrNlE4Ozd3MEK=
DB NFnQWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H3fFQ5yqCq MlfRS2k2OD1|LkWgcm0> M2HQVFIyOjN5NUC4
Pfeiffer M3LDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;oc|Q5yqCq MXrHTVUxRTNwOTDuUS=> MorMNlEzOzd3MEi=
SU-DHL-5 NUjaOGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rkVlQ5yqCq Mnu5S2k2OD1yLkKzJI5O NVXPUpczOjF{M{e1NFg>
SU-DHL-8 M33zTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDvTpprPDkEoHi= MkPaS2k2OD1zLkSgcm0> NXLlTIJQOjF{M{e1NFg>
WSU-DLCL-2 NIPqb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPHOVM1QMLiaB?= MmDaS2k2OD1zLkSgcm0> NUjsb2I5OjF{M{e1NFg>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
体内研究 YM155按3和10 mg/kg皮下注射前列腺移植瘤,结果显示YM155完全抑制PC-3的肿瘤生长,但是重量没有降低,血细胞数也没有下降。药物动力学分析显示YM155作用于肿瘤组织效果很明显。而且,YM155按5 mg/kg作用于PC-3常位移植瘤时肿瘤抑制率达80% 。[1]YM155和γ-射线联用作用于携带H460或Calu6 移植瘤的裸鼠,显示出强抗癌活性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

启动子-荧光酶素报告实验:

使用Pyrobest聚合酶和引物5’-GCGCGCTCGAGTCTAGACATGCGGATATATTC-3’和5’-GCGCGAA-GCTTTGGCGGTTAATGGCGCGC-3’, 从人类基因组DNA中分离2767个碱基对序列的人类survivin基因启动子。在pGL3-Basic质粒的XhoI/HindIII切除位点,内切酶XhoI/HindIII切除产生的PCR片段。产生的质粒称为pSUR-luc。通过DNA测序仪在所有增强序列处测定DNA序列。通过荧光酶素实验,使用短暂转染的HeLa-S3细胞,测定pSUR-luc的活力。使用的pGL3质粒含有SV40启动子和增强子序列。 pSUR-luc和pSV2bsr 质粒通过Lipofectamin2000稳定转染到HeLa细胞中。加入10 μg/mL灭瘟素,根据适当的荧光酶素信号和基因稳定性,筛选HeLa-SURP-luc单一群落。pGL3和pSV2bsr质粒稳定转染到CHO细胞中。加入10 μg/mL灭瘟素,根据适当的荧光酶素信号和基因稳定性,筛选CHO-SV40-luc单一群落。从HeLa-SURP-luc和CHO-SV40-luc群落中获得细胞用于化学筛选。细胞按每孔5×103接种在96孔板上,加入YM155(溶于DMSO中)。24小时后测定荧光酶素活性。通过回归分析计算IC50值。
细胞实验:

[1]

- 合并
  • Cell lines: PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5,和A375细胞
  • Concentrations: ~ 100 nM
  • Incubation Time: 48小时
  • Method:

    PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5,及A375细胞系按5到40×103密度接种在96孔板上。YM155溶解在DMSO中,持续处理细胞48小时。通过sulforhodamine B试剂测定细胞数。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 皮下注射PC-3移植瘤的雄性裸鼠(BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: 皮下注射,每周持续处理3天,处理3周。
    (Only for Reference)

溶解度 (25°C)

体外 Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 443.29
化学式

C20H19BrN4O3

CAS号 781661-94-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Survivin Signaling Pathway Map

相关Survivin产品

Tags: 购买YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide)供应商 | 采购YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide)价格 | YM155 (Sepantronium Bromide)生产 | 订购YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID